Use of the levonorgestrel-releasing intrauterine system and breast cancer

Obstetrics and Gynecology

Volumn 106, Issue 4, 2005, Pages 813-817

  Backman, Tiina ^b   Rauramo, Ilkka ^b   Jaakkola, Kimmo ^b   Inki, Pirjo ^b   Vaahtera, Katja ^b   Launonen, Aino ^b   Koskenvuo, Markku ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LEVONORGESTREL;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CONFIDENCE INTERVAL; DRUG SURVEILLANCE PROGRAM; DRUG USE; FEMALE; FINLAND; FISHER EXACT TEST; HORMONAL CONTRACEPTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 25444444348     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000178754.88912.b9     Document Type: Article

References (17)

1. Backman T, Huhtala S, Blom T, Luoto R, Rauramo I, Koskenvuo M. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. BJOG 2000;107:335-9.
2. Backman T, Huhtala S, Luoto R, Tuominen J, Rauramo I, Koskenvuo M. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol 2002;99:608-13.
3. Backman T, Huhtala S, Tuominen J, Luoto R, Erkkola R, Blom T, et al. Sixty thousand woman-years of experience on the levonorgestrel intrauterine system: an epidemiological survey in Finland. Eur J Contracept Reprod Health Care 2001;6(suppl):23-6.
4. Backman T, Rauramo I, Huhtala S, Koskenvuo M. Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol 2004;190:50-4.
5. Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Blackwell Scientific; Oxford, UK 1987, p. 132-4.
6. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996;347:1713-27.
7. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 2004;190:55-22.
8. International Collaborative Post-Marketing Surveillance of Norplant Meirik O, Parley TMM, Diaz S, et al. Post-marketing surveillance of Norplant contraceptive implants: I. Contraceptive efficacy and reproductive health. Contraception 2001;63:167-86.
9. International Collaborative Post-Marketing Surveillance of Norplant. Meirik O, Parley TMM, Collins J, et al. Post-marketing surveillance of Norplant contraceptive implants: II. Non-reproductive health. Contraception 2001;63:187-209.
10. Sivin I. Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants. Drug Saf 2003;26:303-35.
11. Strom BL, Berlin JA, Weber AL, Norman SA, Bernstein L, Burkman RT, et al. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception 2004;69:353-60.
12. Luukkainen T, Lahteenmaki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med 1990;22:85-90.
13. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry: experience in Finland. Acta Oncol 1994;33:365-9.
14. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001;2:133-40.
15. demons M, Goss P. Estrogen and the risk of breast cancer, [published erratum appears in: N Engl J Med 2001;344:1804]. N Engl J Med 2001;344:276-85.
16. Pukkala E. Cancer risk by social class and occupation: a survey of 109,000 cancer cases among Finns of working age. Basel (Switzerland): Karger, 1995.
17. Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med 1997;16:791-801.